Gap Inc V.GAP

N E W S!

[obeyobey]

PharmaGap Inc.
TSX VENTURE: GAP
OTC Bulletin Board: PHRGF

Feb 11, 2011 08:31 ET
PharmaGap Lead Drug to Be Presented at American Association for Cancer Research 102nd Annual Meeting
OTTAWA, ONTARIO--(Marketwire - Feb. 11, 2011) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") announced today that the Dr. Ken Sokoll, Vice President Clinical Development and Chief Operating Officer for PharmaGap, along with Dr. Barbara Vanderhyden of the Ottawa Hospital Research Institute ("OHRI"), will be presenting results of testing of PharmaGap's lead cancer drug in two separate poster sessions at the American Association for Cancer Research ("AACR") 102nd Annual Meeting in April in Orlando, Florida.
The poster to be presented by PharmaGap is entitled "A Novel PKC inhibitor: Inhibition of Cell Proliferation in Cancer Cell Lines and Pharmacokinetics in Sprague-Dawley Rats". This poster presents further evidence of the ability of GAP-107B8 to inhibit in vitro cell proliferation in various cancer cells. Using two different routes of administration (single bolus injection and continuous infusion) of GAP-107B8 to Sprague Dawley rats has enabled PharmaGap to gather the first pharmacokinetics data for GAP-107B8 following administration in animals. These data provide insight into important parameters such as the half-life, distribution, metabolism and elimination of GAP-107B8 when administered via the intravenous route.
The poster to be presented by the Barbara Vanderhyden lab at OHRI is entitled "Therapeutic Testing of a Novel Inhibitor GAP-107B8 on Ovarian Cancer Cells", and is the product of the ongoing collaboration among Dr. Vanderhyden, the OHRI, and PharmaGap in developing GAP-107B8 for use in treating ovarian cancer. In addition to previously announced results from this program showing efficacy against ovarian cancer cell proliferation in both in vitro and in vivomodels, the poster will present results indicating the effect of GAP-107B8 in inducing apoptosis (programmed cell death), in blocking or delaying progression of ovarian cancer cells through their normal cell cycle and in the reduction of average tumor size due to its therapeutic efficacy.
The AACR 102nd Annual Meeting 2011 will be held from April 2nd to 6th in Orlando, Florida. The AACR gives exhibitors the opportunity to gain visibility for their organizations among more than 18,000 scientists and other cancer professionals who are projected to attend from around the world, and is considered to be the premier networking event for specialists in all areas of cancer research.
About OHRI and Dr. Barbara Vanderhyden
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the University's Faculties of Medicine and Health Sciences. The OHRI includes more than 1,500 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. www.ohri.ca
Dr. Vanderhyden is a Senior Scientist, Cancer Therapeutics at the Ottawa Hospital Research Institute and a Professor in the Departments of Cellular & Molecular Medicine and Obstetrics & Gynecology at the University of Ottawa. She holds the Corinne Boyer Chair in Ovarian Cancer Research. She has published over 60 peer-reviewed journal papers primarily in the area of ovarian cancer and collaborates extensively with many pharmaceutical and biotechnology companies focused on the development of therapies for ovarian cancer.
About PharmaGap Inc.
PharmaGap Inc. (TSX VENTURE:GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug that has been shown to be highly cytotoxic to numerous cancer types, including chemo-resistant cancers, in vitro. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.